Copyright Nasdaq. Minimum 15 minutes delayed.
Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.
Events & Presentations
|Summary Toggle Jun 1-5, 2018 Jun 1, 2018 06/01/18||
Title: Preliminary Results From an Ongoing Phase 2a Study of RX, an Oral Nucleoside Analogue to Treat Advanced Urothelial Cancer (aUC) [View Poster]
Title: Preliminary Report of A Phase 1b/2a Trial, An Oral Inhibitor of Phosphorylated P68 (P-p68), Which Mediates β-catenin Nuclear Translocation in Advanced Triple-Negative Breast Cancer (TNBC) [View Poster]
|Summary Toggle Apr 14-18, 2018 Apr 14, 2018 04/14/18||
Title: RX-3117 promotes epigenetic effects in cancer cells through enhanced degradation of DNMT1 [View Poster]
Jan 9, 2018
12:00 AM PST Jan 9, 2018 12:00 AM PST 01/09/18